Group | AUC | t1/2 | tmax | Cmax | F | CV of F |
---|---|---|---|---|---|---|
μg·hr/ml | hr | hr | μg/ml | % | % | |
CsA Intravenous Administration | ||||||
I | 48.63 ± 7.64 | 12.83 ± 1.64 | ||||
CsA Oral Administration | ||||||
II | 15.02 ± 4.821-c | 11.79 ± 2.56 | 5.47 ± 1.191-c | 0.88 ± 0.301-c | 15.5 ± 4.91-c | 32 |
III | 19.85 ± 5.271-c | 12.85 ± 2.28 | 4.43 ± 1.621-c | 1.32 ± 0.351-c | 20.4 ± 5.41-c | 27 |
IV | 39.95 ± 5.901-a , 1-b | 11.47 ± 1.87 | 1.81 ± 0.751-a , 1-b | 2.73 ± 0.481-a , 1-b | 41.5 ± 6.11-a , 1-b | 15 |
Group I (N = 7): CsA intravenous; group II (N = 8): CsA oily solution; group III (N = 7): CsA oily solution + concomitant TUDC; group IV (N = 8): TUDC-monoolein-CsA micellar solution. Values are expressed as means ± SD. t1/2, half-life; tmax, time to maximum concentration;Cmax, maximum concentration; F, bioavailability.
↵1-a Significantly different from CsA oily solution (p < 0.05).
↵1-b Significantly different from CsA oily solution + concomitant TUDC (p < 0.05).
↵1-c Significantly different from TUDC-monoolein-CsA micellar solution (p < 0.05).